Investigation of blood-brain barrier permeability to magnetite-dextran nanoparticles (MD3) after osmotic disruption in rats.
The permeability of experimentally disrupted blood-brain barrier (BBB) to superparamagnetic nanoparticles (MD3) was studied in rats. BBB opening was induced by intracarotid injection of mannitol. One hundred eighty rats were used for the study. Rats were examined at two time points, 30 minutes and 12 hours after intracarotid mannitol injection. Different preparations intravenously injected 30 minutes before rat sacrifice were used for characterization of BBB disruption. BBB integrity was determined with 99mTc-diethylenetriamine pentaacetic acid (DTPA) and 99mTc-albumin. Iron oxide-glucose particles (12-nm mean diameter), 99mTc-labeled lecithin-cholesterol liposomes of three different sizes (50, 100, and 200 nm), and polyethylene glycol (PEG)-coated 99mTc liposomes (50 nm) were used for investigations of the dependence of BBB permeability on particle system size or surface. Magnetite-dextran nanoparticles (MD3) were evaluated as superparamagnetic contrast agent to monitor with magnetic resonance imaging (MRI) the BBB breakdown. In vitro T1 and T2 relaxation times of the brain tissue were measured at 40 MHz and 37 degrees C, and T2-weighted MR images were acquired at 0.5 T. After intracarotid mannitol infusion, as expected, the BBB breakdown was immediate and temporary as judged by soluble molecule diffusion. MD3 nanoparticles crossed the BBB 12 hours after intravenous mannitol injection, at a time when brain permeability for molecules or small particles returns to normal. Magnetite crystals were found in cytoplasmic vesicles of glial cells. On MRI, signal intensity decreased after injection of MD3, even 12 hours after mannitol injection. This particularity could be useful in the study of focal pathological lesions accompanied by BBB permeability modifications. In such conditions, superparamagnetic particle contrast agents could be caught by the BBB, allowing the observation of impaired BBB areas without detectable cellular lesions.
Rousseau
V
V
Laboratoire de Biophysique Médicale, Faculté de Médecine, Angers, France.
Denizot
B
B
Pouliquen
D
D
Jallet
P
P
Le Jeune
J J
JJ
D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000473:pathology* / Q000648:ultrastructure; D002199:Capillary Permeability / Q000502:physiology*; D003911:Dextrans / Q000493:pharmacokinetics*; D008279:Magnetic Resonance Imaging; D008832:Microchemistry; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar; D016284:Technetium Tc 99m Pentetate / Q000008:administration & dosage; D013997:Time Factors; D018924:Vascular Capacitance
D003911:Dextrans; D016284:Technetium Tc 99m Pentetate